Neuromyelitis optica in Brazil: A study on clinical and prognostic factors

Multiple Sclerosis

Volumn 15, Issue 5, 2009, Pages 613-619

  Bichuetti, Denis B ^a,b   Oliveira, E M L ^a   Souza, N A ^a   Rivero, R L M ^a   Gabbai, A A ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Demyelinating disease; Epidemiology; Magnetic resonance imaging; Neuromyelitis optica; Prognosis

Indexed keywords

AQUAPORIN 4; AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; BRAIN DAMAGE; BRAZIL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PROGNOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SPINAL CORD DISEASE;

ADULT; BRAZIL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROMYELITIS OPTICA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 65349149097     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508101935     Document Type: Article

References (40)

1. Jacob A, Matiello M, Wingerchuk DM, Lucchinetti CF, Pittock SJ, Weinshenker BG. Neuromyelitis optica: Changing concepts. J Neuroimmunol 2007; 187: 126-138.
2. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: A clinicopathological study of 8 patients. Ann Neurol 1993; 34: 162-168.
3. Lucchinetti CF, Mandler RN, McGavern D. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125 (pt 7): 1450-1461.
4. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
5. Lennon VA Wingerchuk DM Kryzer TJ. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
6. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63: 390-396.
7. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
8. Ghezzi A, Bergamaschi R, Martinelli V. Italian Devic's Study Group (IDESG). Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol 2004; 251: 47-52.
9. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-1114.
10. Bergamaschi R, Ghezzi A. Devic's neuromyelitis optica: Clinical features and prognostic factors. Neurol Sci 2004; 25 (Suppl. 4): S364-S367.
11. Merle H, Olindo S, Bonnan M. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007; 114: 810-815.
12. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006;129: 595-605.
13. Lana-Peixoto MA. Devic's neuromyelitis optica: A critical review. Arq Neuropsiquiatr 2008; 66: 120-138.
14. Polman CH, Reingold SC, Edan G. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846.
15. McDonald WI, Compston A, Edan G. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
16. Mandler RN Ahmed W Dencoff JE. Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51: 1219-1220.
17. Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. Neurologist 2007; 13: 2-11.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
19. Weinshenker BG, Bass B, Rice GP. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 1989; 112 (pt 1): 133-146.
20. Bichuetti DB, Rivero RL, Oliveira DM. Neuromyelitis optica: Brain abnormalities in a Brazilian cohort. Arq Neuropsiquiatr 2008; 66: 1-4.
21. Bichuetti DB, Barros TM, Oliveira EM, Annes M, Gabbai AA. Demyelinating disease in patients with myasthenia gravis. Arq Neuropsiquiatr 2008; 66: 5-7.
22. Papais-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M. Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neurosurg Psychiatry 2002; 73: 429-435.
23. Marignier R, De Sèze J, Vukusic S. NMO-IgG and Devic's neuromyelitis optica: A French experience. Mult Scler 2008; 14: 440-445.
24. Rivera JF, Kurtzke JF, Booth VJ. Corona 5th, VT. Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol 2008; 255: 710-715.
25. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007; 68: 603-605.
26. Pittock SJ, Lennon VA, de Seze J. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65: 78-83.
27. Jarius S, Franciotta D, Bergamaschi R. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68: 1076-1077.
28. Paul F, Jarius S, Aktas O. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007;4: E133.
29. Takahashi T, Fujihara K, Nakashima I,. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 2007; 130 (pt 5): 1235-1243.
30. Weinstock-Guttman B. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler 2008; 14: 1061-1067.
31. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006; 63: 964-968.
32. Nakashima I, Fujihara K, Miyazawa I. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 2006; 77: 1073-1075.
33. Bichuetti DB, Rivero RL, Oliceira EM. White matter spectroscopy in neuromyelitis optica: A case control study. J neurol 2008 (Epub ahead of print).
34. Filippi M, Rocca MA, Moiola L. MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology 1999; 53: 1705-1710.
35. Fu L, Matthews PM, De Stefano N. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121 (pt 1): 103-113.
36. Sarchielli P, Presciutti O, Pelliccioli GP. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 1999; 122 (pt 3): 513- 521.
37. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: A geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114 (pt 2): 1045-1056.
38. Weinshenker BG, Bass B, Rice GP. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112 (pt 6): 1419-1428.
39. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003; 60: 848-853.
40. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol 2008; 126: 12-16.